-
-
-
-
-
-
-
Pharvaris B.V. (PHVS) PT Raised to $79 at Citizens on Agent Trial Success
-
-
-
-
-
-
-
Pharvaris publishes AAE-C1INH disease burden study in Frontiers in Immunology
-
-
-
-
-
-
-
Pharvaris presents safety data on combined deucrictibant formulations
-
-
-
-
-
-
-
Pharvaris presents deucrictibant data at allergy conference
-
-
-
-
-
-
-
Pharvaris B.V. (PHVS) Stock Setup is Strong - Cantor Fitzgerald
-
-
-
-
-
-
-
Pharvaris delays RAPIDe-3 study results to Q4 2025
-
-
-
-
-
-
-
Pharvaris (PHVS) Presents Long-Term Clinical Data of Deucrictibant
-
479,030 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


